Literature DB >> 2121328

Branhamella catarrhalis: an organism gaining respect as a pathogen.

B W Catlin1.   

Abstract

Branhamella catarrhalis was formerly regarded as a common, essentially harmless inhabitant of the pharynx. This misapprehension was caused, in part, by confusion with another pharyngeal resident, Neisseria cinerea. The two organisms can now be differentiated by the positive reactions of B. catarrhalis in tests for nitrate reduction and hydrolysis of tributyrin and DNase. B. catarrhalis is currently recognized as the third most frequent cause of acute otitis media and acute sinusitis in young children. It often causes acute exacerbations of chronic bronchopulmonary disease in older or immunocompromised adults and is incriminated occasionally in meningitis, endocarditis, bacteremia, conjunctivitis, keratitis, and urogenital infections. Virulence-associated factors, such as pili, capsules, outer membrane vesicles, iron acquisition proteins, histamine-synthesizing ability, resistance to the bactericidal action of normal human serum, and binding to the C1q complement component, have been identified in some strains. beta-Lactamase producing strains, first detected in 1976, have risen to approximately 75% worldwide. Thus far, however, practically all American strains of B. catarrhalis remain susceptible to alternative antibiotics. A possible selective advantage of recent isolates is their reportedly heightened tendency for adherence to oropharyngeal cells from patients with chronic bronchopulmonary disease.

Entities:  

Mesh:

Year:  1990        PMID: 2121328      PMCID: PMC358165          DOI: 10.1128/CMR.3.4.293

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  279 in total

1.  Neisseria catarrhalis in exudate otitis media.

Authors:  J D Coffey; A D Martin; H N Booth
Journal:  Arch Otolaryngol       Date:  1967-10

2.  Analysis of the relationship between ampicillin resistance and beta-lactamase production in Branhamella catarrhalis.

Authors:  E E Stobberingh; H J van Eck; A W Houben; C P van Boven
Journal:  Drugs       Date:  1986       Impact factor: 9.546

3.  Identification and antimicrobial susceptibility testing of Branhamella catarrhalis in United States laboratories, 1983-1985.

Authors:  R N Jones; H M Sommers
Journal:  Drugs       Date:  1986       Impact factor: 9.546

4.  Detection, distribution and inhibition of Branhamella catarrhalis beta-lactamases.

Authors:  A Philippon; J Y Riou; M Guibourdenche; F Sotolongo
Journal:  Drugs       Date:  1986       Impact factor: 9.546

5.  Branhamella catarrhalis as an indirect pathogen.

Authors:  J K Wardle
Journal:  Drugs       Date:  1986       Impact factor: 9.546

6.  Plasmid-mediated beta-lactamase in Branhamella catarrhalis.

Authors:  C Kamme; I Eliasson; B K Knutson; M Vang
Journal:  Drugs       Date:  1986       Impact factor: 9.546

7.  Clinical and bacteriological evaluation of Branhamella catarrhalis in respiratory infections.

Authors:  A Saito; K Yamaguchi; Y Shigeno; S Kohno; H Shigeno; N Kusano; Y Dotsu; K Hara
Journal:  Drugs       Date:  1986       Impact factor: 9.546

8.  Inhibition of the beta-lactamases of Branhamella catarrhalis by clavulanic acid and other inhibitors.

Authors:  T Farmer; C Reading
Journal:  Drugs       Date:  1986       Impact factor: 9.546

9.  Isoelectric focusing of beta-lactamases from sputum and middle ear isolates of Branhamella catarrhalis recovered in the United States.

Authors:  D R Nash; R J Wallace; V A Steingrube; P A Shurin
Journal:  Drugs       Date:  1986       Impact factor: 9.546

10.  Epidemiological and bacteriological findings on Branhamella catarrhalis respiratory infections in The Netherlands.

Authors:  B I Davies; F P Maesen
Journal:  Drugs       Date:  1986       Impact factor: 9.546

View more
  81 in total

1.  Genome analysis of Moraxella catarrhalis strain BBH18, [corrected] a human respiratory tract pathogen.

Authors:  Stefan P W de Vries; Sacha A F T van Hijum; Wolfgang Schueler; Kristian Riesbeck; John P Hays; Peter W M Hermans; Hester J Bootsma
Journal:  J Bacteriol       Date:  2010-05-07       Impact factor: 3.490

2.  The immunoglobulin D-binding protein MID from Moraxella catarrhalis is also an adhesin.

Authors:  Arne Forsgren; Marta Brant; Mirela Karamehmedovic; Kristian Riesbeck
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

3.  Killing kinetics of five orally administered antibiotics at clinically achievable concentrations against Moraxella catarrhalis.

Authors:  E Bingen; F Bourgeois; H Chardon; C Doit; N Lambert-Zechovsky
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-10       Impact factor: 3.267

4.  Rapid method for differentiating strains of Branhamella catarrhalis.

Authors:  V Peiris; J Heald
Journal:  J Clin Pathol       Date:  1992-06       Impact factor: 3.411

5.  The Moraxella catarrhalis immunoglobulin D-binding protein MID has conserved sequences and is regulated by a mechanism corresponding to phase variation.

Authors:  Andrea Möllenkvist; Therése Nordström; Christer Halldén; Jens Jørgen Christensen; Arne Forsgren; Kristian Riesbeck
Journal:  J Bacteriol       Date:  2003-04       Impact factor: 3.490

6.  Molecular cloning and characterization of outer membrane protein E of Moraxella (Branhamella) catarrhalis.

Authors:  R Bhushan; R Craigie; T F Murphy
Journal:  J Bacteriol       Date:  1994-11       Impact factor: 3.490

7.  The transferrin binding protein B of Moraxella catarrhalis elicits bactericidal antibodies and is a potential vaccine antigen.

Authors:  L E Myers; Y P Yang; R P Du; Q Wang; R E Harkness; A B Schryvers; M H Klein; S M Loosmore
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

8.  A major outer membrane protein of Moraxella catarrhalis is a target for antibodies that enhance pulmonary clearance of the pathogen in an animal model.

Authors:  M E Helminen; I Maciver; J L Latimer; L D Cope; G H McCracken; E J Hansen
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

9.  Lack of serotype-specific antibody response to lipopolysaccharide antigens of Moraxella catarrhalis during lower respiratory tract infection.

Authors:  M Rahman; T Holme; I Jönsson; A Krook
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-04       Impact factor: 3.267

Review 10.  Moraxella catarrhalis: clinical significance, antimicrobial susceptibility and BRO beta-lactamases.

Authors:  K McGregor; B J Chang; B J Mee; T V Riley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-04       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.